About
About Retatrutide Status
An independent tracker for one question, kept current and kept honest.
Independent tracker. Not affiliated with Eli Lilly, the FDA, or any regulatory agency. This site exists to answer one question accurately — what is the regulatory status of retatrutide — and to say so with the source and the date attached.
Why this exists
Retatrutide has produced remarkable trial results, and the writing about it has become correspondingly loose. “FDA approval expected in 2027” appears on pages that elsewhere admit no application has been filed. Filing plans are reported as approval dates. Countdown timers tick toward dates nobody set. Sites that answer “is retatrutide approved?” often sell something further down the page.
The confusion is understandable, because the vocabulary is genuinely confusing. Submission, filing acceptance, PDUFA date, approval and launch are five different things, and four of them sound like the fifth. But the consequence is that people making decisions about their own health read a plan as a promise.
This site keeps those five things apart, on every page, permanently.
What it does
- Checks the FDA's own approval records, the trial registry and Lilly's disclosures on a regular cadence, and timestamps every check.
- Publishes the current status from a single data file, so nothing on the site can contradict anything else.
- Maintains a dated timeline separating what happened from what has not.
- Reports trial results with the duration, population and estimand that make them interpretable, and always with the placebo arm.
- Emails subscribers when something material actually changes — and only then.
- Publishes machine-readable status at /status.json and an RSS feed, so other people can build on the same facts.
What it is not
- Not affiliated with Eli Lilly and Company, the FDA, or any regulator or agency. Nothing here is endorsed by any of them.
- Not a source of medical advice. No dosing, no administration guidance, no clinical recommendations. Full disclaimer.
- Not a seller, and not connected to any. There are no links to vendors of research peptides and there never will be.
- Not medically reviewed. There is no medical reviewer, so no page claims one.
Who writes it
Evan Marsh pen name
Editor
Editor of Retatrutide Status. Evan Marsh is a pen name. The work here is editorial and research: reading regulatory filings, trial registry entries and company disclosures, and reporting what they actually say. Not a physician, pharmacist, researcher or clinician, and nothing on this site is medical advice.
“Evan Marsh” is a pen name, stated plainly here rather than buried. It is not a physician, not a pharmacist, not a researcher and not a clinician, and this site does not attach medical credentials to it.
What the byline does mean is accountability for method: every figure on this site was read from its primary source, every claim points at that source, and every error gets logged in public at /corrections. That is the thing worth judging a tracker on.
How it is funded
Currently it is not. There is no advertising, no sponsorship, no affiliate relationship and no paid placement anywhere on this site.
If that changes it will be disclosed on the editorial policy page and on the page carrying it, before anything is earned. Two categories are permanently excluded: sellers of research chemicals or unapproved peptides, and anyone whose commercial interest depends on this site describing the regulatory status as further along than it is.
How the work is done
The editorial policy sets out the source hierarchy, what counts as a material change, how numbers are handled, and the list of things this site refuses to publish. It is worth reading if you intend to rely on anything here.
Getting in touch
Corrections, questions and source suggestions:alerts@retatrutidestatus.com, orthe contact page. Corrections backed by a primary source get handled fastest.